Related Experiment Video
Updated: Jun 11, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Anticancer Activity of Imidazolyl Gold(I/III) Compounds in Non-Small Cell Lung Cancer Cell Lines
Rossana Galassi1, Nicola Sargentoni1, Sofia Renzi2
1Chemistry Division, School of Science and Technology, University of Camerino, ChIP Via Madonna delle Carceri, 62032 Camerino, Italy.
Abstract:
Lung cancer is a leading cause of cancer-related death worldwide that needs updated therapies to contrast both the serious side effects and the occurrence of drug resistance. A panel of non-small cell lung cancer (NSCLC) cells were herein employed as cancer models. Eight structurally related gold(I) and gold(III) complexes with NHC and halides or triphenylphosphane ligands were investigated as lung cancer cell growth inhibitors. As expected, gold compounds with PPh3 were found to be more cytotoxic than homoleptic [(NHC)2-Au(I)]X or heteroleptic NHC-Au(I)X or NHC-Au(III)X3 complexes. Mixed ligand gold(I) compounds exhibiting the linear NHC-AuPPh3 (compound 7) or the trigonal NHC-Au(Cl)PPh3 (compound 8) arrangements at the central metal were found to be the best lung cancer cytotoxic compounds. Analysis of the TrxR residual activity of the treated cells revealed that these compounds efficiently inhibit the most accredited molecular target for gold compounds, the TrxR, with compound 8 reaching more than 80% activity reduction in lung cells. Some of the current cancer lung therapy protocols consist of specific lung cancer cell cytotoxic agents combined with antifolate drugs; interestingly, the herein gold compounds are both TrxR and antifolate inhibitors. The human DHFR was inhibited with IC50 ranging between 10-21 µM, depending on substrate concentrations, proceeding by a likely allosteric mechanism only for compound 8.
Insights
New gold compounds show promise in treating non-small cell lung cancer (NSCLC). These compounds inhibit thioredoxin reductase (TrxR) and human dihydrofolate reductase (DHFR), offering a dual-action approach against lung cancer cells.
Area of Science:
- Medicinal Chemistry
- Oncology
- Nanotechnology
Background:
- Lung cancer remains a major global health challenge, necessitating novel therapeutic strategies to overcome drug resistance and severe side effects.
- Existing treatments for non-small cell lung cancer (NSCLC) often face limitations, driving the search for more effective and targeted therapies.
Purpose of the Study:
- To investigate the efficacy of novel gold(I) and gold(III) complexes as inhibitors of non-small cell lung cancer (NSCLC) cell growth.
- To identify specific gold compounds with enhanced cytotoxic activity and understand their molecular mechanisms of action.
Main Methods:
- Synthesis and characterization of eight structurally related gold(I) and gold(III) complexes featuring NHC, halide, and triphenylphosphane ligands.
- Evaluation of the cytotoxic effects of these gold complexes on a panel of NSCLC cell lines.
- Assessment of the inhibition of thioredoxin reductase (TrxR) activity and human dihydrofolate reductase (DHFR) by the most potent gold compounds.
Main Results:
- Gold complexes incorporating triphenylphosphane (PPh3) ligands exhibited greater cytotoxicity compared to homoleptic or heteroleptic NHC-gold complexes.
- Mixed-ligand gold(I) compounds, specifically NHC-AuPPh3 (compound 7) and NHC-Au(Cl)PPh3 (compound 8), demonstrated the highest efficacy in inhibiting NSCLC cell growth.
- Compound 8 significantly inhibited TrxR activity (over 80% reduction) and also showed inhibitory effects on human DHFR, suggesting a dual mechanism of action.
Conclusions:
- Novel gold(I) and gold(III) complexes, particularly those with mixed NHC and PPh3 ligands, represent promising candidates for NSCLC therapy.
- The identified gold compounds effectively inhibit TrxR and DHFR, key targets in cancer therapy, offering a potential strategy to overcome drug resistance.
- Compound 8's ability to inhibit both TrxR and DHFR, potentially through an allosteric mechanism on DHFR, warrants further investigation for clinical applications in lung cancer treatment.
